References
- Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, and Nasrallah
GK. Epstein–Barr Virus Epidemiology, Serology, and Genetic
Variability of LMP-1 Oncogene among Healthy Population: An
Update. Frontiers in Oncology 2018;8:211.
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani
R, et al. The 2016 Revision of the World Health Organization
Classification of Lymphoid
Neoplasms. Blood 2016;127:2375–2390.
- Fernandez-Pol S, Silva O, and Natkunam Y. Defining the Elusive
Boundaries of Chronic Active Epstein-Barr Virus
Infection. Haematologica 2018;103: 924–927.
- Cohen JI. Optimal Treatment for Chronic Active Epstein-Barr Virus
Disease. Pediatric Transplantation 2009;13:393–96.
- Roliński J, Grywalska E, Pyzik A, Dzik M, Opoka-Winiarska V, Surdacka
A, Maj M, et al. Interferon Alpha as Antiviral Therapy in Chronic
Active Epstein-Barr Virus Disease with Interstitial Pneumonia - Case
Report. BMC Infectious Diseases 2018;18:190.
- Hongjun B, Xu L, Peng H, Lin Y, Li X, Wang H, and Qin Y. Chronic
Active Epstein-Barr Virus Infection with Systemic Vasculitis and
Pulmonary Arterial Hypertension in a Child. Frontiers in
Pediatrics 2019;7:219.
- Tseng YJ, Ding WQ, Zhong L, Chen J, and Luo ZG. Chronic Active
Epstein–Barr Virus (CAEBV) Enteritis. International Journal of
Infectious Diseases 2019;82:15–17.
- Xiao HJ, Li J, Song HM, Li ZH, Dong M, and Zhou XG. Epstein–Barr
Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as
Gastrointestinal Perforations and Skin Lesions. Medicine2016;95:e2676.
- Cohen, JI, Manoli I, Dowdell K, Krogmann TA, Tamura D, Radecki P, Bu
W, et al. Hydroa Vacciniforme–like Lymphoproliferative Disorder: An
EBV Disease with a Low Risk of Systemic Illness in
Whites. Blood 2019;133:2753–2764.
- Dávila
Saldaña
BJ, John
T, Bonifant
C, Buchbinder
D, Chandra
S, Chandrakasan
S, Chang
W, Chen
L, et al. High risk of relapsed disease in patients with NK/T-cell
chronic active Epstein-Barr virus disease outside of Asia. Blood
Adv 2022;6:452-459.
- Bollard CM and Cohen JI. How I Treat T-Cell Chronic Active
Epstein-Barr Virus Disease. Blood 2018;131: 2899–2905.
- Dimitrova D, Gea-Banacloche J, Steinberg SM, Sadler JL, Hicks SN,
Carroll E, Wilder JS, et al. Prospective Study of a Novel,
Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform
for Primary Immunodeficiency Diseases. Biology of Blood and
Marrow Transplantation 2020;26:94–106.
- Gupta G, Man I, and Kemmett D. Hydroa Vacciniforme: A Clinical and
Follow-up Study of 17 Cases. Journal of the American Academy of
Dermatology 2000;42:208–213.
- Nitiyarom R, and Wongpraparut C. Hydroa Vacciniforme and Solar
Urticaria. Dermatologic Clinics 2014;32:345–53.
- Hirai Y, Yamamoto T, Kimura H, Ito Y, Tsuji K, Miyake T, Morizane S,
Suzuki D, Fujii K, and Iwatsuki K. Hydroa Vacciniforme Is Associated
with Increased Numbers of Epstein–Barr Virus–Infected γδ T
Cells. Journal of Investigative
Dermatology 2012;132:1401–1408.
- Quintanilla-Martinez L, and Fend F. Deciphering Hydroa
Vacciniforme. Blood 2019;133:2735–2737.
- Kimura H and Fujiwara S. Overview of EBV-Associated T/NK-Cell
Lymphoproliferative Diseases. Frontiers in
Pediatrics 2019;6:417.
- Kawa K, Okamura T, Yasui M, Sato E, and Inoue M. Allogeneic
Hematopoietic Stem Cell Transplantation for Epstein–Barr
Virus-Associated T/NK-Cell Lymphoproliferative Disease. Critical
Reviews in Oncology/Hematology 2002;44: 251–257.
- Sawada A and Inoue M. Hematopoietic Stem Cell Transplantation for the
Treatment of Epstein-Barr Virus-Associated T- or NK-Cell
Lymphoproliferative Diseases and Associated Disorders. Frontiers
in Pediatrics 2018;6:334.
- Guo N, Chen Y, Wang Y, Huang Y, Feng Y, Li M, and Rao H.
Clinicopathological Categorization of Hydroa Vacciniforme-like
Lymphoproliferative Disorder: An Analysis of Prognostic Implications
and Treatment Based on 19 Cases. Diagnostic
Pathology 2019;14:82.
- Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop
HE, and Rooney CM. Epstein-Barr Virus (EBV)-Specific Cytotoxic T
Lymphocytes for the Prevention and Treatment of EBV-Associated
Post-Transplant Lymphomas. Immunosurveillance,
Immunodeficiencies and Lymphoproliferations , 2002;159:123–133.
- Kim YJ, Choi SY, Lee WJ, Won CH, Chang SE, Choi JH, and Lee MW. Two
Cases of Hydroa Vacciniforme-like Lymphoproliferative Disease
Controlled by Anti-Inflammatory Agents. Photodermatology,
Photoimmunology & Photomedicine 2017;33:287–290.
- Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, Martinez MT, Pajares R,
Montes-Moreno S, Casavilca S, et al. EBV-Associated Cutaneous
NK/T-Cell Lymphoma. American Journal of Surgical
Pathology 2010;34:1773–1782.
- Cohen J, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM,
Gottschalk S, et al. Characterization and Treatment of Chronic Active
Epstein-Barr Virus Disease: A 28-Year Experience in the United States.Blood 2011;22:5835-5849.
- Sawada A, Inoue M, and Kawa K. How We Treat Chronic Active
Epstein–Barr Virus Infection. International Journal of
Hematology 2017;4:406-418.
- Kawa K, Sawada A, Sato M, Okamura T, Sakata N, Kondo O, Kimoto T, et
al. Excellent Outcome of Allogeneic Hematopoietic SCT with
Reduced-Intensity Conditioning for the Treatment of Chronic Active EBV
Infection. Bone Marrow Transplantation 2010;46:77–83.
- Xiao H, Hu B, Luo R, Hu H, Zhang J, Kuang W, Zhang R, et al. Chronic
active Epstein–Barr virus infection manifesting as coronary artery
aneurysm and uveitis. Virol J 2020;17:166-175.
- Ba H, Xu L, Peng H, Lin Y, Li X, Wang H, and Qin Y. Chronic Active
Epstein-Barr Virus Infection with Systemic Vasculitis and Pulmonary
Arterial Hypertension in a Child. Frontiers in
Pediatrics 2019;7:219.
- Murakami K, Ohsawa M, Hu SX, Kanno H, Aozasa K, and Nose M.
Large-Vessel Arteritis Associated with Chronic Active Epstein-Barr
Virus Infection. Arthritis & Rheumatism 1998;41:369–373.